Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

QB3@953 signs collaboration agreement with GSK to identify early-stage drug discovery opportunities QB3@953, a San Francisco incubator created by QB3, a University of California (UC) research institute and biotech accelerator, announced an agreement with pharmaceutical company GSK to identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients.
Drug Research > Drug Discovery & Development > News
Bristol-Myers, QIMR to discover new immuno-oncology antibodies By PBR Staff Writer
Bristol-Myers Squibb (BMS) has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute for the discovery of new therapeutic antibodies against an undisclosed immuno-oncology (I-O) target.
Drug Research > Drug Discovery & Development > News Soligenix gets additional NIAID funding to advance development of OrbeShield in GI ARS Soligenix (SNGX), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Symic Biomedical gets $1.5m NIH Phase II SBIR grant to develop proteoglycan mimetic therapeutics
Platform therapeutic company Symic Biomedical (Symic) announced that it has received a $1.5m Phase II SBIR grant from the National Institutes of Health (NIH) to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.
Drug Research > Drug Discovery & Development > News
Ironshore begins second Phase III trial of HLD-200 in pediatric ADHD patients
By PBR Staff Writer
Canada-based Highland Therapeutics' subsidiary Ironshore Pharmaceuticals has started dosing in the second of two pivotal trials of HLD-200, a next-generation formulation of methylphenidate for patients with attention-deficit/hyperactivity disorder (ADHD).
Drug Research > Drug Discovery & Development > News
HedgePath launches clinical trial for proposed cancer treatment
HedgePath Pharmaceuticals (HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced enrollment has commenced in its Phase II SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.
Drug Research > Drug Discovery & Development > News
Vital Therapies' Phase III trial of ELAD System in patients with AILD failed to meet primary endpoint
Vital Therapies (VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting the treatment of liver failure, today announced that topline results from VTI-208, the Company's phase 3 randomized, controlled, open-label trial, evaluating the ELAD System in subjects with alcohol-induced liver decompensation (AILD) failed to meet the primary endpoint of overall survival through at least 91 days assessed using the Kaplan Meier statistical method.
Drug Research > Drug Discovery & Development > News
Roche and Janus partner to develop TLR inhibitor for autoimmune diseases
By PBR Staff Writer
Swiss drugmaker Roche has partnered with Janus Biotherapeutics to develop a small molecule toll-like receptor (TLR) inhibitor with the potential to address various autoimmune diseases.
Drug Research > Drug Discovery & Development > News
BioLineRx begins Phase IIb trial of new AML consolidation treatment BL-8040
By PBR Staff Writer
Israeli biopharmaceutical firm BioLineRx has started a Phase IIb trial for BL-8040 as a new consolidation treatment for patients with acute myeloid leukemia (AML).
Drug Research > Drug Discovery & Development > News
Pfenex wins $143.5m BARDA contract to develop new anthrax vaccine
By PBR Staff Writer
US-based biotechnology firm Pfenex has secured a five-year $143.5m contract from the biomedical research arm of the US Department of Health and Human Services (HHS) to develop Px563L, a mutant recombinant protective antigen (rPA) anthrax vaccine.
Drug Research > Drug Discovery & Development > News
Chemoswed becomes Chemoswed
It has been broadly announced, that DuPont made a decision to separate the Performance Chemicals segment, creating two strong, independent companies by mid-2015.
Drug Research > Drug Discovery & Development > Press Releases
Renewed GMP Certificate
Following inspections which took place late 2014, Chemoswed has received an updated certificate of GMP compliance. The certificate was issued by the Swedish Medical Products Agency, and covers all manufacturing facilities, i. e. kilolab, pilot plant, and the main manufacturing plant.
Drug Research > Drug Discovery & Development > Press Releases
Sydney researchers advance drug discovery for melanoma treatment
By PBR Staff Writer
Researchers at the Centenary Institute at the University of Sydney have advanced the development of a new class of drugs for the treatment of certain cases of melanoma.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests